Content about Sulfonylurea

February 1, 2012
Study: Link between diabetes drugs, pancreatic cancer risk unclear

A new study published in the American Journal of Gastroenterology examined the possible link between pancreatic cancer and drugs designed to treat diabetes, and found the association to be unclear.

NEW YORK — A new study published in the American Journal of Gastroenterology examined the possible link between pancreatic cancer and drugs designed to treat diabetes, and found the association to be unclear.

Researchers conducted a case-control study based on the British-based General Practice Research Database, which included drug prescriptions, diagnostics, hospitalizations and fatality information. The researchers also took into consideration such factors as body mass index, smoking, alcohol consumption and diabetes duration.

June 27, 2011
Novo Nordisk's Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin

Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.

SAN DIEGO — Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.

The drug maker found that combining Victoza (liraglutide [rDNA origin] injection) with metformin and/or sulfonylurea helped patients achieve blood-sugar control.

March 15, 2011
Study: Metformin best first-line diabetes treatment

While several drugs to treat Type 2 diabetes are on the market, researchers have found that the best first-line option is metformin.

NEW YORK — While several drugs to treat Type 2 diabetes are on the market, researchers have found that the best first-line option is metformin.

Led by Wendy Bennett, an assistant professor of medicine at Johns Hopkins University School of Medicine in Baltimore, researchers reviewed 140 trials and 26 observational studies of head-to-head comparisons of monotherapy or combination therapy that reported intermediate or long-term clinical outcomes or harms of six oral diabetes medications.

September 19, 2010
Sanofi-Aventis: Lantus provides further blood-sugar reduction for patients with Type 2 diabetes

An injected insulin made by French drug maker Sanofi-Aventis provided further reduction of blood sugar...

PARIS An injected insulin made by French drug maker Sanofi-Aventis provided further reduction of blood sugar in patients with Type 2 diabetes when added to oral diabetes drugs, according to a study presented at a medical conference in Sweden.